Loading company…
ZYMEDI develops drug discovery tools and therapies for pulmonary, liver, and cancer conditions.
Founded in 2019 and based in Incheon, South Korea, ZYMEDI develops medicines using its HOMEOS platform and ARS-related databases and AI tools. Its pipeline includes an antibody targeting KARS1 for pulmonary arterial hypertension, a KARS1 inhibitor for NASH, and a pan-KRAS inhibitor for KRAS-mutated tumors. Co-founders are CEO Sunghoon Kim and CTO Nam Hoon Kwon. In January 2025, the company received USD 4.5 million in grant funding from Korea Institute for Advancement of Technology.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in